PRIME THERAPEUTICS for PRIME THERAPEUTICS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. H.R. 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Medicare/Medicaid MMM
H.R. 6800: HEROES Act, Sec. 30205 Requiring Coverage Under Medicare PDPs and MA-PD Plans Without the Imposition of Cost Sharing or Utilization Management Requirements of Drugs Intended to Treat COVID-During Certain Emergencies. S. 4469: COVID-19 Treatment Coverage Act Sec. 6 Coverage of COVID-19 Drugs at no cost sharing under Medicare prescription drug plans. Value-based contracting and Medicaid Best Price. Implementation of Sec. 20003 the SUPPORT Act for Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, to amend Title XVIII of the Social Security Act to allow for the offering of additional prescription drug plans under Medicare Part D. Presidential Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen, issued July 24, 2020 requiring the completion of rulemaking to exclude from safe harbor protection drug rebates in Medicare Part D. Presidential Executive Order on Lowering Drug Prices by Putting America First, issued September 13, 2020 creating a Most Favored Nation Price for drugs in Medicare Part B and Part D. Outreach on pharmacy direct and indirect remuneration in Medicare Part D and on real time benefit tools.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.